CeriBell (NASDAQ:CBLL) VP Sells $20,573.05 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 859 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $23.95, for a total transaction of $20,573.05. Following the sale, the vice president owned 35,899 shares of the company’s stock, valued at approximately $859,781.05. This represents a 2.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $23,851.86.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded up $0.01 during midday trading on Tuesday, reaching $23.95. 243,381 shares of the company were exchanged, compared to its average volume of 457,237. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $25.33. The stock has a fifty day simple moving average of $19.77 and a 200 day simple moving average of $19.27. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The stock has a market cap of $919.20 million, a P/E ratio of -13.61 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, research analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in shares of CeriBell by 6,424.8% during the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after buying an additional 374,179 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of CeriBell by 109.9% during the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after buying an additional 17,177 shares during the last quarter. New York State Common Retirement Fund boosted its position in CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after acquiring an additional 5,200 shares during the period. Quantbot Technologies LP boosted its holdings in shares of CeriBell by 70.3% in the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after acquiring an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. bought a new position in CeriBell during the 2nd quarter valued at $197,000.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. BTIG Research lifted their price target on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Canaccord Genuity Group boosted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.40.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.